MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR

SAVANNAH, Ga.— October 9, 2007— MIT Holding, Inc. (OTCBB: MITD), in collaboration with MEVLABS and Georgia Southern University, have successfully tested prototype designs of the patent pending PROVECTOR™. This small dispensable device is designed to stop the development of pathogens and parasites found in mosquitoes that carry deadly diseases such as malaria, dengue fever, and West Nile virus. The PROVECTOR will initially be made available in countries where such diseases are a major threat to the health of the population. MIT intends to distribute the PROVECTOR internationally to licensees through worldwide distribution partnerships.

The PROVECTOR uses visual, olfactory and chemical signals to attract mosquitoes, which ingest anti-malarial and anti-viral treatments that inhibit the development of the pathogens within the mosquito. The two current principal methods of controlling malaria are drug treatment of patients and the application of pesticides, which can both be very expensive, particularly in developing countries. Additionally, increases in drug resistance of the parasite, as well as widespread insecticide resistance in mosquitoes, cause these current methods to be less effective. Preliminary tests of prototypes of the PROVECTOR have indicated a reduction in the dengue viruses and malaria carried by mosquitoes. The Company is continuing to refine its prototypes prior to commercialization.

Dr. Thomas M. Kollars, Jr., Chief Scientific Advisor of MIT Holding and Chief Executive Officer of MEVLABS, commented, “The PROVECTOR provides a safe and economical solution to the health threat that mosquitoes carrying infectious disease pose to humans. Malaria currently infects over one hundred million people worldwide and kills at least a million people every year, mostly children. Dengue fever is also currently on the rise worldwide, causing illness in hundreds of thousands of people. Dengue cases have also been reported on the border of the United States. The PROVECTOR geographically eradicates the problem while preventing negative impact within the ecosystem.”

William C. Parker, Chief Executive Officer of MIT Holding, Inc., said, “This is a major breakthrough in stopping the spread of infectious disease such as malaria, dengue, and the West Nile virus. Our goal in developing this product is to address and help alleviate the four major problems surrounding mosquito-carrying infectious disease: occurrence of drug-resistant malaria, absence of a vaccine for dengue, population of insecticide resistant mosquitoes, and the current cost of malaria and dengue control. The PROVECTOR device can be used both within households and outdoors and is intended to be available at an affordable price, reducing the financial burden that current treatments often carry. Working in tandem with MEVLABS and Georgia Southern University, MIT Holding is honored to be at the forefront of developing the PROVECTOR, a possible solution to the growing, devastating, worldwide problems that these infectious diseases inflict on the global population.”

Through its wholly owned subsidiaries, MIT distributes wholesale pharmaceuticals in the United States and overseas, administers intravenous infusions, operates ambulatory centers where therapies are administered and sells and rents home medical equipment. MIT is based in Savannah, Georgia and operates an ambulatory care center in Savannah. MIT is establishing relationships with government agencies and distributors outside the United States in order to purchase and sell pharmaceuticals internationally. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Dominican Republic, Haiti, Costa Rica, the Bahamas, Argentina and Brazil. MIT’s domestic wholesale pharmaceutical distribution is conducted through Medical Infusion Technologies, Inc., which sells pharmaceuticals to end-users and other wholesalers in the U.S. MIT plans to form a subsidiary to distribute pharmaceuticals to locations outside of the United States and another subsidiary for sales to institutions, such as hospitals and nursing homes. MIT provides infusion pharmacy services through its pharmacy in Savannah, Georgia. The licensed pharmacy can dispense infusible and non-infusible prescription pharmaceuticals to treat a wide range of chronic and acute health conditions. The home medical equipment division carries a wide variety of durable medical equipment and supplies for purchase or lease. The division maintains inventory and can rapidly obtain a wide variety of home medical equipment products to match almost any request.

Some of the information contained in this release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities and Exchange Act of 1934 the “Exchange Act”), which mean that they relate to events or transactions that have not yet occurred, our expectations or estimates for our future operations, our growth strategies or business plans or other facts that have not yet occurred. These statements can be identified by the use of forward-looking terminology such as “might,” “may,” “could,” “expect,” “anticipate,” “estimate,” “likely,” “intend,” “believe,” or “continue” or the negative thereof or other variations thereon or comparable terminology. For an explanation of some of the risks and uncertainties facing MIT and its investors, please see our most recent prospectus on file with the Securities Exchange Commission. The risk factors contained therein should be considered by prospective investors for their potential impact on forward-looking statements included in this release. These important factors, among others that might not be listed, may cause actual results to differ materially and adversely from the results expressed or implied by the forward-looking statements. We caution investors that such discussions of important risks and uncertainties are not exclusive, and our business may be subject to other risks and uncertainties, which are not detailed there.

Investors are cautioned not to place undue reliance on our forward-looking statements. We make forward-looking statements as of the date of this release, and we assume no obligation to update the forward-looking statements after the date hereof whether as a result of new information or events, changed circumstances, or otherwise, except as required by law.